MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.03% | 4.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.03% | 4.37% | |||
| Cost of Revenue | -3.13% | 2.42% | |||
| Gross Profit | -8.68% | 8.34% | |||
| SG&A Expenses | -6.64% | -2.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 389.58% | 122.25% | |||
| Total Operating Expenses | -2.78% | 1.88% | |||
| Operating Income | -6.84% | 7.55% | |||
| Income Before Tax | -7.74% | 29.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.74% | 29.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.74% | 29.52% | |||
| EBIT | -6.84% | 7.55% | |||
| EBITDA | -21.16% | 7.24% | |||
| EPS Basic | -4.26% | 28.79% | |||
| Normalized Basic EPS | -11.11% | 6.90% | |||
| EPS Diluted | -4.26% | 28.79% | |||
| Normalized Diluted EPS | -11.11% | 6.90% | |||
| Average Basic Shares Outstanding | 1.55% | 0.27% | |||
| Average Diluted Shares Outstanding | 1.55% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
